Krystal Biotech, Inc. KRYS Debt-to-equity

Debt-to-equity at other companies

Sarepta Therapeutics, Inc.SRPT

0.1×0.0×

Ultragenyx PharmaceuticalRARE

3.7×—

Viridian Therapeutics, Inc.VRDN

0.2×+0.1×

RegenxbioRGNX

1×+0.6×

Zevra Therapeutics, Inc.ZVRA

0×-0.5×

Kyverna Therapeutics, Inc.KYTX

0×0.0×

FAQ

What is Krystal Biotech, Inc.'s debt-to-equity?

Krystal Biotech, Inc. (KRYS) reported debt-to-equity of 0× in Q1 2026.

How has Krystal Biotech, Inc.'s debt-to-equity changed year-over-year?

Krystal Biotech, Inc.'s debt-to-equity decreased by 27.6% year-over-year, from 0× to 0×.

What is the long-term trend for Krystal Biotech, Inc.'s debt-to-equity?

Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s debt-to-equity has grown at a -10.6% compound annual growth rate (CAGR), from 0× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.